ArticleJournal of lipid research2009
The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis.
Article in Journal of lipid research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 275 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
275 citing papers in PubMed, 5 syntheses or guidelines pooled it, 596 citations in OpenAlex.
- Effects of exercise on high-density lipoprotein levels in middle-aged and older individuals: A systematic review and meta-analysis.Medicine · 2025Pooled it
- High-density lipoprotein cholesterol efflux capacity and incidence of coronary artery disease and cardiovascular mortality: a systematic review and meta-analysis.Lipids in health and disease · 2022Pooled it
- Moderate alcohol consumption and lipoprotein subfractions: a systematic review of intervention and observational studies.Nutrition reviews · 2022Pooled it
- High-density lipoprotein cholesterol efflux capacity is inversely associated with cardiovascular risk: a systematic review and meta-analysis.Lipids in health and disease · 2017Pooled it
- Seven functional polymorphisms in the CETP gene and myocardial infarction risk: a meta-analysis and meta-regression.PloS one · 2014Pooled it
- Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial.Journal of the American Heart Association · 2020Trial
- Cholesterol efflux capacity, HDL cholesterol, and risk of coronary heart disease: a nested case-control study in men.Journal of lipid research · 2019Trial
- Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux Capacity.Journal of clinical pharmacology · 2019Trial
- Effects of garlic on brachial endothelial function and capacity of plasma to mediate cholesterol efflux in patients with coronary artery disease.Anatolian journal of cardiology · 2017Trial
- Ezetimibe Increases Endogenous Cholesterol Excretion in Humans.Arteriosclerosis, thrombosis, and vascular biology · 2017Trial
- Trial
- Review
- Top-Down Mass Spectrometry and Its Current Applications in Biomarker Discovery in Aging and Age-Related Diseases.International journal of molecular sciences · 2026Review
- Article
- Genetic determinants of lipid metabolism in cardioprotection: From mechanisms to clinical practice.Biomolecules & biomedicine · 2025Review
- Beyond High-density Lipoprotein-cholesterol: Unraveling the Complexity of High-density Lipoprotein Functionality.Journal of atherosclerosis and thrombosis · 2025Review
- Distinct roles of size-defined HDL subpopulations in cardiovascular disease.Current opinion in lipidology · 2025Review
- Article
- HDLR-SR-BI Expression and Cholesterol Uptake are Regulated via Indoleamine-2,3-dioxygenase 1 in Macrophages under Inflammation.Langmuir : the ACS journal of surfaces and colloids · 2025Article
- Postoperative cholesterol changes as early predictors of breast cancer-related lymphedema: a retrospective cohort study.Breast cancer (Tokyo, Japan) · 2025Article
215 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Reverse cholesterol transport (RCT) is a term used to describe the efflux of excess cellular cholesterol from peripheral tissues and its return to the liver for excretion in the bile and ultimately the feces. It is believed to be a critical mechanism by which HDL exert a protective effect on the development of atherosclerosis. In this paradigm, cholesterol is effluxed from arterial macrophages to extracellular HDL-based acceptors through the action of transporters such as ABCA1 and ABCG1. After efflux to HDL, cholesterol may be esterified in the plasma by the enzyme lecithin:cholesterol acyltransferase and is ultimately transported from HDL to the liver, either directly via the scavenger receptor BI or after transfer to apolipoprotein B-containing lipoproteins by the cholesteryl ester transfer protein. Methods for assessing the integrated rate of macrophage RCT in animals have provided insights into the molecular regulation of the process and suggest that the dynamic rate of macrophage RCT is more strongly associated with atherosclerosis than the steady-state plasma concentration of HDL cholesterol. Promotion of macrophage RCT is a potential therapeutic approach to preventing or regressing atherosclerotic vascular disease, but robust measures of RCT in humans will be needed in order to confidently advance RCT-promoting therapies in clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.